Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.44 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.44 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.40 |
| ▸ | ANPEP | P15144 | 2/20 | 0.40 |
| ▸ | ERAP2 | Q6P179 | 2/20 | 0.40 |
| ▸ | RAD52 | P43351 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | EPHX1 | P07099 | 5/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.39 |
| ▸ | NPC1 | O15118 | 2/20 | 0.39 |
| ▸ | RAB9A | P51151 | 2/20 | 0.39 |
| ▸ | ADH1B | P00325 | 1/20 | 0.39 |
| ▸ | ADH1C | P00326 | 1/20 | 0.39 |
| ▸ | ADH1A | P07327 | 1/20 | 0.39 |
| ▸ | ADH4 | P08319 | 1/20 | 0.39 |
| ▸ | CA12 | O43570 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL431070 | 1.00 | KDM4E (0.52) | KDM4EALDH1A1HSD17B10DPP7HRH3 | |
| SCHEMBL32666148 | 0.97 | KDM4E (0.50) | KDM4EALDH1A1HSD17B10DPP7HRH3 | |
| Hydrochloric Acid SCHEMBL9011511 | 0.94 | KDM4E (0.48) | KDM4EALDH1A1HSD17B10DPP7HRH3 | |
| SCHEMBL15534200 | 0.91 | KDM4E (0.46) | KDM4EALDH1A1HSD17B10DPP7HRH3 | |
| SCHEMBL3054314 | 0.90 | KDM4E (0.42) | KDM4EALDH1A1HSD17B10DPP7HRH3 | |
| SCHEMBL23813169 | 0.85 | KDM4E (0.46) | KDM4EALDH1A1HSD17B10DPP7HRH3 | |
| Carbamic Acid SCHEMBL9312692 | 0.83 | KDM4E (0.45) | KDM4EALDH1A1SMN1; SMN2ANPEPERAP2 | |
| SCHEMBL2200783 | 0.82 | — | — | |
| SCHEMBL18602503 | 0.81 | — | — | |
| SCHEMBL455085 | 0.80 | RAD52 (0.56) | KDM4EALDH1A1HSD17B10DPP7HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 765 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260028304-A1 | PROCESS FOR CONTINUOUS CATALYTIC HYDROGENATION OF MDA | EVONIK OPERATIONS GMBH (DE) | 2026-01-29 | — | — | US | claimed |
| US-20260027536-A1 | PROCESS FOR CONTINUOUS CATALYTIC HYDROGENATION OF MDA | EVONIK OPERATIONS GMBH (DE) | 2026-01-29 | — | — | US | claimed |
| US-20260027535-A1 | PROCESS FOR CONTINUOUS CATALYTIC HYDROGENATION OF MDA | EVONIK OPERATIONS GMBH (DE) | 2026-01-29 | — | — | US | claimed |
| US-20260028305-A1 | PROCESS FOR CONTINUOUS CATALYTIC HYDROGENATION OF MDA | EVONIK OPERATIONS GMBH (DE) | 2026-01-29 | — | — | US | claimed |
| US-20260028306-A1 | PROCESS FOR PRODUCING METHYLENEBIS(CYCLOHEXYLAMINE) | EVONIK OPERATIONS GMBH (DE) | 2026-01-29 | — | — | US | claimed |
| EP-4684871-A1 | PROCESS FOR THE CONTINUOUS CATALYTIC HYDROGENATION OF MDA | Evonik Operations GmbH (DE) | 2026-01-28 | — | — | EP | claimed |
| EP-4685133-A1 | PROCESS FOR THE CONTINUOUS CATALYTIC HYDROGENATION OF MDA | Evonik Operations GmbH (DE) | 2026-01-28 | — | — | EP | claimed |
| EP-4685131-A1 | PROCESS FOR THE CONTINUOUS CATALYTIC HYDROGENATION OF MDA | Evonik Operations GmbH (DE) | 2026-01-28 | — | — | EP | claimed |
| EP-4685130-A1 | PROCESS FOR THE PREPARATION OF METHYLENEBIS(CYCLOHEXYLAMINE) | Evonik Operations GmbH (DE) | 2026-01-28 | — | — | EP | claimed |
| EP-4685132-A1 | PROCESS FOR THE CONTINUOUS CATALYTIC HYDROGENATION OF MDA | Evonik Operations GmbH (DE) | 2026-01-28 | — | — | EP | claimed |
| EP-0328291-B1 | HALOGENATED POLYBUTADIENE SERIES ELASTOMERS, METHOD OF PRODUCING THE SAME, AND RUBBER COMPOSITIONS FOR TIRES CONTAINING THE ELASTOMER | Bridgestone Corporation (JP) | 1992-04-29 | — | — | EP | claimed |
| US-4954199-A | REACTION PRODUCT OF POLYHYDROXY POLYETHER, DIAMINE OR TRIAMINE, ORGANIC ISOCYANATE | MOBAY CORPORATION (US) | 1990-09-04 | — | — | US | claimed |
| EP-0328291-A1 | Halogenated polybutadiene series elastomers, method of producing the same, and rubber compositions for tires containing the elastomer | Bridgestone Corporation (JP) | 1989-08-16 | — | — | EP | claimed |
| US-4804405-A | DIAMINOMETHANE DERIVATIVE; OPTIONAL ANTIDOTE | ESZAKMAGYARORSZAGI VEGYIMUVEK (HU) | 1989-02-14 | — | — | US | claimed |
| EP-0199666-A1 | Controlling the rate of diamine curing agents in polyurethane cements | GOODYEAR AEROSPACE CORPORATION (US) | 1986-10-29 | — | — | EP | claimed |
| EP-0104531-B1 | CYCLOALIPHATIC DIISOCYANATES, POSSIBLY IN THE FORM OF A MIXTURE OF ISOMERS, METHOD FOR THEIR PREPARATION AND THEIR USE AS STARTING PRODUCTS IN THE PREPARATION OF SYNTHETIC PRODUCTS OF THE POLYURETHANE TYPE | BAYER AG (DE) | 1985-11-21 | — | — | EP | claimed |
| US-4554299-A | KETIMINE, EPOXY RESIN CEMENT, POLYESTER-URETHANE COPOLYMER | GOODYEAR AEROSPACE CORPORATION (US) | 1985-11-19 | — | — | US | claimed |
| EP-0014207-A1 | EPOXY SURFACER CEMENTS CURED WITH POLYAMINE-KETIMINE MIXTURES | AMERON, INC. (US) | 1980-08-20 | — | — | EP | claimed |
| EP-0014207-A4 | EPOXY SURFACER CEMENTS CURED WITH POLYAMINE-KETIMINE MIXTURES. | AMERON INC (US) | 1980-03-18 | — | — | EP | claimed |
| WO-1979000903-A1 | EPOXY SURFACER CEMENTS CURED WITH POLYAMINE-KETIMINE MIXTURES | AMERON INC (US) | 1979-11-15 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260027535-A1 | PROCESS FOR CONTINUOUS CATALYTIC HYDROGENATION OF MDA | MDH1, MDH2, GPX1 | KDM4E 4415/4885ALDH1A1 76/4885HSD17B10 362/4885 |
| US-20260028305-A1 | PROCESS FOR CONTINUOUS CATALYTIC HYDROGENATION OF MDA | MPO, MDH1, MDH2 | KDM4E 3487/4885ALDH1A1 90/4885HSD17B10 442/4885 |
| US-20260027536-A1 | PROCESS FOR CONTINUOUS CATALYTIC HYDROGENATION OF MDA | MPO, MDH1, MDH2 | KDM4E 4297/4885ALDH1A1 92/4885HSD17B10 572/4885 |
| US-20260028304-A1 | PROCESS FOR CONTINUOUS CATALYTIC HYDROGENATION OF MDA | MPO, CAT, MDH1 | KDM4E 3775/4885ALDH1A1 96/4885HSD17B10 504/4885 |
| US-20260028306-A1 | PROCESS FOR PRODUCING METHYLENEBIS(CYCLOHEXYLAMINE) | MVD, PNMT, HNMT | KDM4E 324/4885ALDH1A1 2150/4885HSD17B10 459/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.